Hodgkin lymphoma: open trials in China

10 open trials have a site in China. Registry data; only the trial team decides who can take part.

NCT07519772
A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
Trial Treatment · Phase 1/2 · Merck Sharp & Dohme LLC
Beijing Cancer hospital (Site 1701), Beijing · Fujian Provincial Cancer Hospital.. (Site 1704), Fuzhou · Sun Yat-Sen University Cancer Center (Site 1712), Guangzhou · Fudan University Shanghai Cancer Center (Site 1711), Shanghai · Henan Cancer Hospital (Site 1702), Zhengzhou
Registry updated 2026-10-29
NCT06526793
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
Trial Treatment · Phase 2 · AstraZeneca
Chengdu · Guangzhou · Nanchang · Nanjing · Nantong · Shandong · Shanghai · Tianjin · Zhengzhou
Registry updated 2026-10-14
NCT06137144
AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
Trial Treatment · Phase 1/2 · AstraZeneca
Beijing · Guangzhou · Shanghai
Registry updated 2026-10-13
NCT07641010
PD-1 Antibody and JAK1 Inhibitor for Newly Diagnosed Pediatric Hodgikin's Lympoma
Trial Treatment · Phase 1/2 · Shanghai Jiao Tong University School of Medicine
Xuzhou Children's Hospital, Xuzhou
Registry updated 2026-06-11
NCT07623850
A Phase I Study of JLM019 Injection
Trial Treatment · Phase 1 · Jecho Biopharmaceuticals Co., Ltd.
Peking Union Medical College Hospital, Beijing
Registry updated 2026-06-03
NCT06487624
An Engineered Sirpα Fused to Anti-Pd-L1 And Tgf-β Fusion Protein (HCB301) in Subjects With Selected Advanced Tumors
Trial Treatment · Phase 1 · FBD Biologics Limited
Zhejiang Provincial Cancer Hospital, Hangzhou · The First Affiliated Hospital Zhejiang University School of Medicine, Hangzhou · Xuzhou Central Hospital, Xuzhou · Yantai Yuhuangding Hospital, Yantai · Southern Medical University Zhujiang Hospital, Zhujiang
Registry updated 2026-04-13
NCT06170489
A Phase III Clinical Study Comparing JS004 Plus Toripalimab With Investigator-Selected Chemotherapy in Patients With PD-(L)1monoclonal Antibody Refractory Classic Hodgkin Lymphoma (cHL)
Trial Treatment · Phase 3 · Shanghai Junshi Bioscience Co., Ltd.
Beijing Cancer Hospital, Beijing
Registry updated 2025-02-28
NCT06494371
A Study of LCAR-HL30 in Subjects With Relapsed/Refractory Hodgkin's Lymphoma and Anaplastic Large Cell Lymphoma
Trial Treatment · Phase 1 · Ruijin Hospital
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai
Registry updated 2024-07-10
NCT06203652
The Pathogenesis and Prognostic Factors of Lymphoma
Research · Shanghai Zhongshan Hospital
Zhongshan Hospital,Fudan University, Shanghai
Registry updated 2024-01-12
NCT02259556
CD30-directed Chimeric Antigen Receptor T (CART30) Therapy in Relapsed and Refractory CD30 Positive Lymphomas
Trial Treatment · Phase 1/2 · Chinese PLA General Hospital
Chinese PLA General Hospital, Beijing
Registry updated 2016-01-28

All Hodgkin lymphoma trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error